"Maybe but according to these initial results - ZLD outperforms Lyrica"
Yup, totally agree there from what they said.
Now (imo) they'll probably look at doing a CR on the back of the improving sp (and sentiment) to pitch themselves against the top-selling generics.
If their confidence is that strong, they should really not waste any time and go straight to the FDA.
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica, page-35
Add ZLD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.340M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.0¢ | 466 | 1 |
View Market Depth
| Last trade - 16.12pm 08/10/2024 (20 minute delay) ? |
| ZLD (ASX) Chart |
Day chart unavailable